WO1999012576A3 - Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy - Google Patents
Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy Download PDFInfo
- Publication number
- WO1999012576A3 WO1999012576A3 PCT/US1998/019267 US9819267W WO9912576A3 WO 1999012576 A3 WO1999012576 A3 WO 1999012576A3 US 9819267 W US9819267 W US 9819267W WO 9912576 A3 WO9912576 A3 WO 9912576A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- natriuretic peptide
- atrial natriuretic
- nucleic acid
- acid encoding
- tissue kallikrein
- Prior art date
Links
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 title abstract 5
- 101800001288 Atrial natriuretic factor Proteins 0.000 title abstract 5
- 101800001890 Atrial natriuretic peptide Proteins 0.000 title abstract 5
- 101710176219 Kallikrein-1 Proteins 0.000 title abstract 5
- 102000057032 Tissue Kallikreins Human genes 0.000 title abstract 5
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 title abstract 5
- 208000020446 Cardiac disease Diseases 0.000 title abstract 4
- 208000019622 heart disease Diseases 0.000 title abstract 4
- 208000017169 kidney disease Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000000747 cardiac effect Effects 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 abstract 8
- 150000007523 nucleic acids Chemical class 0.000 abstract 8
- 102000039446 nucleic acids Human genes 0.000 abstract 8
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a method for treating a nonhypertension-associated renal disorder in a subject having a nonhypertension associated renal disorder, comprising administering to the subject a nucleic acid encoding tissue kallikrein and/or a nucleic acid encoding atrial natriuretic peptide under conditions whereby the nucleic acid encoding tissue kallikrein and/or the nucleic acid encoding atrial natriuretic peptide is expressed in a cell in the subject, thereby treating a nonhypertension-associated renal disorder. Also provided is a method of treating a nonhypertension-associated cardiac disorder in a subject having a nonhypertension-associated cardiac disorder, comprising administering to the subject a nucleic acid encoding tissue kallikrein and/or a nucleic acid encoding atrial natriuretic peptide under conditions whereby the nucleic acid encoding tissue kallikrein and/or the nucleic acid encoding atrial natriuretic peptide is expressed in a cell in the subject, thereby treating the nonhypertension-associated cardiac disorder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU94876/98A AU9487698A (en) | 1997-09-11 | 1998-09-11 | Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5851197P | 1997-09-11 | 1997-09-11 | |
| US60/058,511 | 1997-09-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1999012576A2 WO1999012576A2 (en) | 1999-03-18 |
| WO1999012576A3 true WO1999012576A3 (en) | 1999-06-03 |
Family
ID=22017263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1998/019267 WO1999012576A2 (en) | 1997-09-11 | 1998-09-11 | Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU9487698A (en) |
| WO (1) | WO1999012576A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9102707B2 (en) | 2011-08-30 | 2015-08-11 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5043900A (en) * | 1999-05-24 | 2000-12-12 | Mayo Foundation For Medical Education And Research | Adenovirus vectors encoding brain natriuretic peptide |
| US6407211B1 (en) * | 1999-12-17 | 2002-06-18 | Mayo Foundation For Medical Education And Research | Chimeric natriuretic peptides |
| DK2001518T3 (en) | 2006-03-30 | 2013-10-07 | Palatin Technologies Inc | Cyclic natriuretic peptide preparations |
| US8580746B2 (en) | 2006-03-30 | 2013-11-12 | Palatin Technologies, Inc. | Amide linkage cyclic natriuretic peptide constructs |
| EP2004633A4 (en) | 2006-03-30 | 2009-08-26 | Palatin Technologies Inc | Linear natriuretic peptide constructs |
| WO2010078325A2 (en) | 2008-12-29 | 2010-07-08 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides for reducing or preventing restenosis |
| WO2013103896A1 (en) | 2012-01-06 | 2013-07-11 | Mayo Foundation For Medical Education And Research | Treating cardiovascular or renal diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5668618A (en) * | 1979-11-06 | 1981-06-09 | Green Cross Corp:The | Remedy for disease related to disorder of circulatory organ consisting essentially of kallikrein of human urine |
-
1998
- 1998-09-11 AU AU94876/98A patent/AU9487698A/en not_active Abandoned
- 1998-09-11 WO PCT/US1998/019267 patent/WO1999012576A2/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5668618A (en) * | 1979-11-06 | 1981-06-09 | Green Cross Corp:The | Remedy for disease related to disorder of circulatory organ consisting essentially of kallikrein of human urine |
Non-Patent Citations (8)
| Title |
|---|
| H. MURAKAMI ET AL: "Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats", KIDNEY INTERNATIONAL, vol. 53, 1998, pages 1305 - 1313, XP002099190 * |
| H. S. MARGOLIUS: "Tissue Kallikreins and Kinins: Regulation and Roles in Hypertensive and Diabetic Diseases", ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, vol. 29, 1989, pages 343 - 364, XP002099188 * |
| J. CHAO ET AL: "Experimental Kallikrein Gene Therapy in Hypertension, Cardiovascular and Renal Diseases", PHARMACOLOGICAL RESEARCH, vol. 35, no. 6, 1997, pages 517 - 522, XP002099186 * |
| J. CHAO ET AL: "Human Kallikrein Gene Delivery Attenuates Hypertension, Cardiac Hypertrophy , and Renal Injury in Dahl Salt-Sensitive Rats", HUMAN GENE THERAPY, vol. 9, 1 January 1998 (1998-01-01), pages 21 - 31, XP002099183 * |
| KUEI-FU LIN ET AL: "Atrial Natriuretic Peptide Gene Delivery Attenuates Hypertension, Cardiac Hypertrophy, and Renal Injury in Salt-Sensitive Rats", HUMAN GENE THERAPY, vol. 9, 1 July 1998 (1998-07-01), pages 1429 - 1438, XP002099184 * |
| KUEI-FU LIN ET AL: "Human Atrial Natriuretic Peptide Gene Delivery Reduces Blood Pressure in Hypertensive Rats", HYPERTENSION, vol. 26, no. 6(1), December 1995 (1995-12-01), pages 847 - 853, XP002099187 * |
| L. JIN ET AL: "Gene Therapy in Hypertension: Adenovirus-Mediated Kallikrein Gene Delivery in Hypertensive Rats", HUMAN GENE THERAPY, vol. 8, 10 October 1997 (1997-10-10), pages 1753 - 1761, XP002099185 * |
| PATENT ABSTRACTS OF JAPAN vol. 5, no. 132 (C - 068) 22 August 1981 (1981-08-22) * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9102707B2 (en) | 2011-08-30 | 2015-08-11 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides |
| US9441027B2 (en) | 2011-08-30 | 2016-09-13 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides |
| US9587004B2 (en) | 2011-08-30 | 2017-03-07 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999012576A2 (en) | 1999-03-18 |
| AU9487698A (en) | 1999-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1997012986A3 (en) | Non-group c adenoviral vectors | |
| AU2681497A (en) | Novel agouti-related gene | |
| CA2257133A1 (en) | Human dnase i hyperactive variants | |
| WO1998014596A3 (en) | Disease associated protein tyrosine phosphatases | |
| WO1999006554A3 (en) | 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES | |
| WO2001079444A3 (en) | Albumin fusion proteins | |
| AU7587696A (en) | Differentiation-suppressive polypeptide | |
| WO1999006549A3 (en) | 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN TESTIS AND OTHER TISSUES | |
| WO2001070977A3 (en) | Fibroblast growth factor receptor-like molecules and uses thereof | |
| WO2001068854A3 (en) | Fibroblast growth factor-like molecules and uses thereof | |
| WO1999012576A3 (en) | Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy | |
| WO2000009754A3 (en) | HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS | |
| WO1998011234A3 (en) | Human protein kinases | |
| WO1998010085A3 (en) | Gene therapy for congestive heart failure | |
| NZ331063A (en) | Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition | |
| WO1999054447A3 (en) | Human nucleic acid sequences of bladder tumour tissue | |
| WO2000063415A8 (en) | Dna encoding the human vanilloid receptor vr1 | |
| WO2000008157A3 (en) | Human anion transporter genes atnov | |
| AU8811298A (en) | Novel peptides and polypeptides useful for regenerating the nervous system | |
| AU1867297A (en) | Gene-therapeutic nucleic acid construct, production of same and use of same in the treatment of heart disorders | |
| WO1999058098A3 (en) | HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO | |
| WO2000029589A8 (en) | Methioninase gene therapy for tumor treatment | |
| WO2001054707A3 (en) | Modification of surface proteins by aminopeptidase inhibitors | |
| WO2001048164A3 (en) | Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure | |
| WO1995034649A3 (en) | Polycystic kidney disease 1 gene and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |